• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗磷脂抗体的存在是抗磷脂综合征或相关疾病患者血栓事件的一个危险因素。

Presence of antiphospholipid antibody is a risk factor in thrombotic events in patients with antiphospholipid syndrome or relevant diseases.

机构信息

Department of Dermatology, Mie University Graduate School of Medicine, Mie, Tsu, Japan.

出版信息

Int J Hematol. 2013 Mar;97(3):345-50. doi: 10.1007/s12185-013-1277-0. Epub 2013 Feb 3.

DOI:10.1007/s12185-013-1277-0
PMID:23378183
Abstract

Antiphospholipid antibodies (aPL) including lupus anticoagulant (LA), anticardiolipin antibodies (aCL) IgG and aCL-β2-glycoprotein I (β2GPI) complex IG are causative factors for thrombotic event (THE). We retrospectively investigated relationships between aPLs and THE in 458 patients suspected of having antiphospholipid syndrome. THEs were observed in 232 of 458 patients, including 148 cases of venous thrombosis, 59 of arterial thrombosis, 18 of microthrombosis, and 20 of complications of pregnancy. The frequency of THE was significantly high in patients positive for LA and/or aPL. In patients with autoimmune disease (AID), the frequency of THE was significantly high in patients with any types of aPLs. Additionally, risk of THE was significantly increased in patients with more than two types of aPLs. Prolonged activated partial thromboplastin time indicated a high risk for THE. However, neither thrombocytopenia nor AID was a risk for THE. In conclusion, the presence of aPL is an indicator for high risk of THE in patients in whom THE was suspected. However, the risk of THE in aPL-positive patients varied among patients with different underlying diseases.

摘要

抗磷脂抗体(aPL)包括狼疮抗凝物(LA)、抗心磷脂抗体(aCL)IgG 和β2-糖蛋白 I(β2GPI)复合物 Ig,是血栓事件(THE)的致病因素。我们回顾性调查了 458 例疑似抗磷脂综合征患者的 aPL 与 THE 之间的关系。在 458 例患者中观察到 232 例 THE,包括 148 例静脉血栓形成、59 例动脉血栓形成、18 例微血栓形成和 20 例妊娠并发症。LA 和/或 aPL 阳性患者的 THE 发生率显著升高。在自身免疫性疾病(AID)患者中,任何类型的 aPL 患者的 THE 发生率均显著升高。此外,aPL 类型超过两种的患者发生 THE 的风险显著增加。延长的活化部分凝血活酶时间表明 THE 风险较高。然而,血小板减少症和 AID 均不是 THE 的危险因素。总之,在疑似 THE 的患者中,存在 aPL 是 THE 高风险的指标。然而,aPL 阳性患者的 THE 风险在不同基础疾病的患者中存在差异。

相似文献

1
Presence of antiphospholipid antibody is a risk factor in thrombotic events in patients with antiphospholipid syndrome or relevant diseases.抗磷脂抗体的存在是抗磷脂综合征或相关疾病患者血栓事件的一个危险因素。
Int J Hematol. 2013 Mar;97(3):345-50. doi: 10.1007/s12185-013-1277-0. Epub 2013 Feb 3.
2
Presence of Antiphospholipid Antibodies as a Risk Factor for Thrombotic Events in Patients with Connective Tissue Diseases and Idiopathic Thrombocytopenic Purpura.抗磷脂抗体作为结缔组织病和特发性血小板减少性紫癜患者血栓形成事件的危险因素
Intern Med. 2016;55(6):589-95. doi: 10.2169/internalmedicine.55.5536. Epub 2016 Mar 15.
3
Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study.无症状携带者中持续性抗磷脂抗体(aPL)作为未来血栓形成事件的危险因素:一项全国性前瞻性研究。
Lupus. 2014 Dec;23(14):1468-76. doi: 10.1177/0961203314545410. Epub 2014 Aug 27.
4
Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies.高滴度抗心磷脂抗体和多种抗磷脂抗体患者的血栓栓塞风险
Thromb Haemost. 2003 Jul;90(1):108-15.
5
Frequency of vascular and pregnancy morbidity in patients with low vs. moderate-to-high titers of antiphospholipid antibodies.抗磷脂抗体低滴度与中高滴度患者的血管和妊娠发病率
Blood Coagul Fibrinolysis. 2015 Apr;26(3):261-6. doi: 10.1097/MBC.0000000000000218.
6
Added value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome: lessons learned from year-long routine measurements.非标准抗磷脂抗体对抗磷脂综合征的附加价值:来自长达一年的常规测量中得到的经验教训。
Clin Rheumatol. 2019 Feb;38(2):371-378. doi: 10.1007/s10067-018-4251-7. Epub 2018 Aug 11.
7
Multiple antiphospholipid antibodies positivity and antiphospholipid syndrome criteria re-evaluation.多种抗磷脂抗体阳性与抗磷脂综合征标准的重新评估
Lupus. 2014 Oct;23(12):1252-4. doi: 10.1177/0961203314531635.
8
[Following 90 patients with antiphospholipid syndrome with antibody titers and correlations with clinical manifestations: symptoms of the disease, a new antibody and correlations with clinical manifestations in the Israeli population].[90例抗磷脂综合征患者的抗体滴度及其与临床表现的相关性:疾病症状、一种新抗体及其与以色列人群临床表现的相关性]
Harefuah. 2001 Jun;140(6):495-500, 565.
9
Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: a longitudinal study.抗磷脂抗体患者血小板计数的血栓风险分层:一项纵向研究。
J Thromb Haemost. 2017 Sep;15(9):1782-1787. doi: 10.1111/jth.13763. Epub 2017 Aug 5.
10
IgA anticardiolipin and IgA anti-β2 glycoprotein I antibody positivity determined by fluorescence enzyme immunoassay in primary antiphospholipid syndrome.通过荧光酶免疫测定法测定原发性抗磷脂综合征中 IgA 抗心磷脂和 IgA 抗β2 糖蛋白 I 抗体的阳性情况。
Clin Chem Lab Med. 2014 Sep;52(9):1329-33. doi: 10.1515/cclm-2014-0039.

引用本文的文献

1
Thrombosis associated with infection (Review).感染相关的血栓形成(综述)
Exp Ther Med. 2021 Sep;22(3):967. doi: 10.3892/etm.2021.10399. Epub 2021 Jul 7.
2
Advances in the Research on Anticardiolipin Antibody.抗心磷脂抗体研究进展。
J Immunol Res. 2019 Dec 1;2019:8380214. doi: 10.1155/2019/8380214. eCollection 2019.
3
Pro‑atherogenic activation of A7r5 cells induced by the oxLDL/β2GPI/anti‑β2GPI complex.氧化型低密度脂蛋白/β2 糖蛋白 I/抗β2 糖蛋白 I 复合物诱导 A7r5 细胞的动脉粥样硬化形成激活。

本文引用的文献

1
Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities.抗磷脂抗体特异性 23 种可能组合对系统性红斑狼疮中抗磷脂综合征诊断的临床准确性评估。
J Thromb Haemost. 2012 Dec;10(12):2512-8. doi: 10.1111/jth.12014.
2
Predominant prevalence of arterial thrombosis in Japanese patients with antiphospholipid syndrome.日本抗磷脂综合征患者以动脉血栓形成为主要表现。
Lupus. 2012 Dec;21(14):1506-14. doi: 10.1177/0961203312458469. Epub 2012 Aug 30.
3
Anti-phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome.
Int J Mol Med. 2018 Oct;42(4):1955-1966. doi: 10.3892/ijmm.2018.3805. Epub 2018 Aug 2.
抗磷脂酰乙醇胺抗体、血栓栓塞事件与抗磷脂综合征。
Autoimmun Rev. 2012 Dec;12(2):230-4. doi: 10.1016/j.autrev.2012.07.008. Epub 2012 Jul 13.
4
Antiphospholipid syndrome: laboratory testing and diagnostic strategies.抗磷脂综合征:实验室检测与诊断策略。
Am J Hematol. 2012 May;87 Suppl 1(Suppl 1):S75-81. doi: 10.1002/ajh.23196. Epub 2012 Mar 31.
5
The role of complement in the antiphospholipid syndrome: a novel mechanism for pregnancy morbidity.补体在抗磷脂综合征中的作用:一种导致妊娠不良的新机制。
Semin Arthritis Rheum. 2012 Aug;42(1):66-9. doi: 10.1016/j.semarthrit.2012.01.001. Epub 2012 Mar 8.
6
Reevaluation of predictive value of ACL and anti-β2GP1 antibody for thrombosis in patients with systemic lupus erythematosus: from a perspective of a practical world.重新评估 ACL 和抗β2GP1 抗体对系统性红斑狼疮患者血栓形成的预测价值:从实际情况出发。
Rheumatol Int. 2012 Dec;32(12):3881-6. doi: 10.1007/s00296-011-2267-2. Epub 2011 Dec 23.
7
ISTH/SSC lupus anticoagulant testing guidelines: how far have these been adopted by laboratories?国际血栓与止血学会/标准化委员会狼疮抗凝物检测指南:实验室对这些指南的采用情况如何?
J Thromb Haemost. 2011 Oct;9(10):2117-9. doi: 10.1111/j.1538-7836.2011.04448.x.
8
APS--controversies in diagnosis and management, critical overview of current guidelines.APS--诊断和管理中的争议,当前指南的批判性概述。
Thromb Res. 2011 Feb;127 Suppl 3:S51-2. doi: 10.1016/S0049-3848(11)70014-7.
9
An international multicentre-laboratory evaluation of a new assay to detect specifically lupus anticoagulants dependent on the presence of anti-beta2-glycoprotein autoantibodies.一种新的检测方法特异性检测狼疮抗凝物的国际多中心实验室评估,该方法依赖于抗β2-糖蛋白自身抗体的存在。
J Thromb Haemost. 2011 Jan;9(1):149-53. doi: 10.1111/j.1538-7836.2010.04068.x.
10
Antiphospholipid syndrome.抗磷脂综合征。
Lancet. 2010 Oct 30;376(9751):1498-509. doi: 10.1016/S0140-6736(10)60709-X. Epub 2010 Sep 6.